The Effect Of Probiotics On Gut Microbiota And Inflammatory Markers In Individuals With IBD

Abstract

Inflammatory bowel disease (IBD) is a chronic, debilitating condition with increasing global prevalence. Probiotics have gained attention as a potential adjunct therapy, but their precise effects on clinical outcomes, inflammatory markers, and gut microbiota composition remain an area of active investigation.We conducted a randomized controlled trial with 200 IBD patients, divided into two groups: a probiotic group and a placebo group. Clinical scores, remission rates, adverse events, inflammatory markers (C-reactive protein, TNF-α, IL-6), and gut microbiota composition (Firmicutes, Bacteroidetes, and other phyla) were evaluated.

 Our results revealed a statistically significant reduction in clinical scores (p < 0.05) and a higher remission rate in the probiotic group (75%) compared to the placebo group (65%). Inflammatory markers, including C-reactive protein, TNF-α, and IL-6, exhibited a significant decrease (p < 0.05) in the probiotic group. Notably, the Firmicutes/Bacteroidetes ratio, a crucial indicator of gut health, saw a statistically significant increase (p < 0.05) in the probiotic group.This study demonstrates the promising impact of probiotic intervention in IBD management, with improvements in clinical scores, remission rates, inflammatory markers, and a favorable shift in gut microbiota composition. These findings underscore the potential of probiotics as a complementary therapy in IBD, with implications for more personalized treatment approaches in the future.